Effects of Victoza (Liraglutide) Versus Lyxumia (Lixisenatide) on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 02 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Oct 2021 Results (n=50) assessing the distinct effects of a long-acting (liraglutide) and a short-acting (lixisenatide) glucagon-like peptide-1 receptor agonist (GLP-1 RA) on macronutrient intake, gastrointestinal side effects and pancreas function in people with type-2-diabetes mellitus, published in the Diabetes, Obesity and Metabolism.
25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
09 Jul 2020 Results (n=57) assessing effects of lixisenatide versus liraglutide on esophageal and gastric function in patients with type 2 diabetes, published in the Diabetes Care

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com